Health Condition 1: N289- Disorder of kidney and ureter, unspecified
Conditions
Interventions
Intervention1: Oral Hydroxychloroquine: Patients will receive oral HCQ (hydroxychloroquine sulfate tablets
Immulast provided by Cipla Pharmaceutical Co, Ltd) in a dose of 400mg/day(300mg/day if weight60kg) for 6 months along with optimized dose of ACEi/ARB
Control Intervention1: Supportive therapy: Patien
Sponsors
None
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult patients(=18 years AND 2. Persistent urinary protein creatinine ratio >1g/g but less than 3.5g/g 3. eGFR=45 ml/min/1.73m2 as calculated by the chronic kidney disease epidemiology collaboration creatinine equation (CKD-EPI) 4. Has been on ACEi/ARB therapy for at-least 6 months in maximal tolerated dose
Exclusion criteria
Exclusion criteria: 1. Use of immunosuppression in the past 6 months 2. IgAN requiring immunosuppression like crescentic IgAN or IgA vasculitis 3. Current or planned pregnancy or lactation 4. Concomitant systemic disease like diabetes, chronic liver disease, malignancy, any cardiac or cerebrovascular disease 5. Retinopathy 6. G6PD deficiency 7. Unwilling to give consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| •The primary outcome studied will be the proportion of patients who achieve remission(complete/partial) at the end of 6 months in both the groups. Timepoint: At 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome will be (1) Difference in the percentage reduction in proteinuria between the two groups (2) Difference in renal survival defined as decline in eGFR of 40% or progression to end stage renal disease(ESRD) at the end of 6 months between the two groups Timepoint: At 6 months | — |
Countries
India
Contacts
Public ContactSoumita Bagchi
Department of Nephrology
Outcome results
None listed